Aurora Investment Counsel Decreases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aurora Investment Counsel decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 37.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 19,054 shares of the medical equipment provider’s stock after selling 11,340 shares during the period. Lantheus comprises 1.1% of Aurora Investment Counsel’s investment portfolio, making the stock its 27th largest position. Aurora Investment Counsel’s holdings in Lantheus were worth $2,091,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in LNTH. Moloney Securities Asset Management LLC purchased a new stake in Lantheus during the 3rd quarter valued at $1,066,000. Hancock Whitney Corp boosted its position in shares of Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after buying an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Lantheus in the 2nd quarter worth about $290,000. Pitcairn Co. raised its position in Lantheus by 117.0% in the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock worth $521,000 after buying an additional 4,509 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the period. Institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several recent research reports. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, JMP Securities decreased their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Price Performance

NASDAQ:LNTH opened at $86.45 on Thursday. The company has a market cap of $6.01 billion, a price-to-earnings ratio of 14.38 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock’s 50 day simple moving average is $103.76 and its two-hundred day simple moving average is $96.59.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.